| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.003 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.16 | 0.003 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.096 | 0.003 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.004 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.21 | 0.004 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.15 | 0.006 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.006 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.009 |